Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor

CD4+CD25+Foxp3+T cell population is heterogenous and contains three major sub-groups. First, thymus derived T regulatory cells (tTreg) that are naïve/resting. Second, activated/memory Treg that are produced by activation of tTreg by antigen and cytokines. Third, effector lineage CD4+CD25+T cells gen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bruce M. Hall, Rachael M. Hall, Giang T. Tran, Catherine M. Robinson, Paul L. Wilcox, Prateek K. Rakesh, Chuanmin Wang, Alexandra F. Sharland, Nirupama D. Verma, Suzanne J. Hodgkinson
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	interleukin-5 transplant tolerance T regulatory cells cytokines allograft rejection chronic rejection Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/886ca1e1c5ef4eb18f1eef7445395015
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:886ca1e1c5ef4eb18f1eef7445395015
record_format	dspace
spelling	oai:doaj.org-article:886ca1e1c5ef4eb18f1eef74453950152021-12-01T13:37:38ZInterleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor1664-322410.3389/fimmu.2021.714838https://doaj.org/article/886ca1e1c5ef4eb18f1eef74453950152021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.714838/fullhttps://doaj.org/toc/1664-3224CD4+CD25+Foxp3+T cell population is heterogenous and contains three major sub-groups. First, thymus derived T regulatory cells (tTreg) that are naïve/resting. Second, activated/memory Treg that are produced by activation of tTreg by antigen and cytokines. Third, effector lineage CD4+CD25+T cells generated from CD4+CD25- T cells’ activation by antigen to transiently express CD25 and Foxp3. We have shown that freshly isolated CD4+CD25+T cells are activated by specific alloantigen and IL-4, not IL-2, to Ts2 cells that express the IL-5 receptor alpha. Ts2 cells are more potent than naïve/resting tTreg in suppressing specific alloimmunity. Here, we showed rIL-5 promoted further activation of Ts2 cells to Th2-like Treg, that expressed foxp3, irf4, gata3 and il5. In vivo, we studied the effects of rIL-5 treatment on Lewis heart allograft survival in F344 rats. Host CD4+CD25+T cells were assessed by FACS, in mixed lymphocyte culture and by RT-PCR to examine mRNA of Ts2 or Th2-like Treg markers. rIL-5 treatment given 7 days after transplantation reduced the severity of rejection and all grafts survived ≥60d whereas sham treated rats fully rejected by day 31 (p<0.01). Treatment with anti-CD25 or anti-IL-4 monoclonal antibody abolished the benefits of treatment with rIL-5 and accelerated rejection. After 10d treatment with rIL-5, hosts’ CD4+CD25+ cells expressed more Il5ra and responded to specific donor Lewis but not self. Enriched CD4+CD25+ cells from rIL-5 treated rats with allografts surviving >60 days proliferated to specific donor only when rIL-5 was present and did not proliferate to self or third party. These cells had more mRNA for molecules expressed by Th2-like Treg including Irf4, gata3 and Il5. These findings were consistent with IL-5 treatment preventing rejection by activation of Ts2 cells and Th2-like Treg.Bruce M. HallBruce M. HallRachael M. HallRachael M. HallGiang T. TranGiang T. TranCatherine M. RobinsonCatherine M. RobinsonPaul L. WilcoxPaul L. WilcoxPrateek K. RakeshPrateek K. RakeshChuanmin WangAlexandra F. SharlandNirupama D. VermaNirupama D. VermaSuzanne J. HodgkinsonSuzanne J. HodgkinsonFrontiers Media S.A.articleinterleukin-5transplant toleranceT regulatory cellscytokinesallograft rejectionchronic rejectionImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	interleukin-5 transplant tolerance T regulatory cells cytokines allograft rejection chronic rejection Immunologic diseases. Allergy RC581-607
spellingShingle	interleukin-5 transplant tolerance T regulatory cells cytokines allograft rejection chronic rejection Immunologic diseases. Allergy RC581-607 Bruce M. Hall Bruce M. Hall Rachael M. Hall Rachael M. Hall Giang T. Tran Giang T. Tran Catherine M. Robinson Catherine M. Robinson Paul L. Wilcox Paul L. Wilcox Prateek K. Rakesh Prateek K. Rakesh Chuanmin Wang Alexandra F. Sharland Nirupama D. Verma Nirupama D. Verma Suzanne J. Hodgkinson Suzanne J. Hodgkinson Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor
description	CD4+CD25+Foxp3+T cell population is heterogenous and contains three major sub-groups. First, thymus derived T regulatory cells (tTreg) that are naïve/resting. Second, activated/memory Treg that are produced by activation of tTreg by antigen and cytokines. Third, effector lineage CD4+CD25+T cells generated from CD4+CD25- T cells’ activation by antigen to transiently express CD25 and Foxp3. We have shown that freshly isolated CD4+CD25+T cells are activated by specific alloantigen and IL-4, not IL-2, to Ts2 cells that express the IL-5 receptor alpha. Ts2 cells are more potent than naïve/resting tTreg in suppressing specific alloimmunity. Here, we showed rIL-5 promoted further activation of Ts2 cells to Th2-like Treg, that expressed foxp3, irf4, gata3 and il5. In vivo, we studied the effects of rIL-5 treatment on Lewis heart allograft survival in F344 rats. Host CD4+CD25+T cells were assessed by FACS, in mixed lymphocyte culture and by RT-PCR to examine mRNA of Ts2 or Th2-like Treg markers. rIL-5 treatment given 7 days after transplantation reduced the severity of rejection and all grafts survived ≥60d whereas sham treated rats fully rejected by day 31 (p<0.01). Treatment with anti-CD25 or anti-IL-4 monoclonal antibody abolished the benefits of treatment with rIL-5 and accelerated rejection. After 10d treatment with rIL-5, hosts’ CD4+CD25+ cells expressed more Il5ra and responded to specific donor Lewis but not self. Enriched CD4+CD25+ cells from rIL-5 treated rats with allografts surviving >60 days proliferated to specific donor only when rIL-5 was present and did not proliferate to self or third party. These cells had more mRNA for molecules expressed by Th2-like Treg including Irf4, gata3 and Il5. These findings were consistent with IL-5 treatment preventing rejection by activation of Ts2 cells and Th2-like Treg.
format	article
author	Bruce M. Hall Bruce M. Hall Rachael M. Hall Rachael M. Hall Giang T. Tran Giang T. Tran Catherine M. Robinson Catherine M. Robinson Paul L. Wilcox Paul L. Wilcox Prateek K. Rakesh Prateek K. Rakesh Chuanmin Wang Alexandra F. Sharland Nirupama D. Verma Nirupama D. Verma Suzanne J. Hodgkinson Suzanne J. Hodgkinson
author_facet	Bruce M. Hall Bruce M. Hall Rachael M. Hall Rachael M. Hall Giang T. Tran Giang T. Tran Catherine M. Robinson Catherine M. Robinson Paul L. Wilcox Paul L. Wilcox Prateek K. Rakesh Prateek K. Rakesh Chuanmin Wang Alexandra F. Sharland Nirupama D. Verma Nirupama D. Verma Suzanne J. Hodgkinson Suzanne J. Hodgkinson
author_sort	Bruce M. Hall
title	Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor
title_short	Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor
title_full	Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor
title_fullStr	Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor
title_full_unstemmed	Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor
title_sort	interleukin-5 (il-5) therapy prevents allograft rejection by promoting cd4+cd25+ ts2 regulatory cells that are antigen-specific and express il-5 receptor
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/886ca1e1c5ef4eb18f1eef7445395015
work_keys_str_mv	AT brucemhall interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT brucemhall interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT rachaelmhall interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT rachaelmhall interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT giangttran interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT giangttran interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT catherinemrobinson interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT catherinemrobinson interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT paullwilcox interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT paullwilcox interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT prateekkrakesh interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT prateekkrakesh interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT chuanminwang interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT alexandrafsharland interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT nirupamadverma interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT nirupamadverma interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT suzannejhodgkinson interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor AT suzannejhodgkinson interleukin5il5therapypreventsallograftrejectionbypromotingcd4cd25ts2regulatorycellsthatareantigenspecificandexpressil5receptor
_version_	1718405127710179328

Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor

Ejemplares similares